COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan.
BCG
Bacillus Calmette–Guérin
COVID-19
SARS-CoV-2
coronavirus disease 2019
severity
vaccination
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
18 04 2021
18 04 2021
Historique:
received:
11
03
2021
revised:
15
04
2021
accepted:
16
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
6
5
2021
Statut:
epublish
Résumé
Data have not been reported to explore the relation between COVID-19 severity and BCG vaccination status at the individual patient level. Taiwan has a nationwide neonatal BCG vaccination program that was launched in 1965. The Taiwan Centers for Disease Control established a web-based National Immunization Information System (NISS) in 2003 and included all citizens' BCG vaccination records in NISS for those born after 1985. We identified COVID-19 Taiwanese patients born after 1985 between 21 January and 19 March 2021. Study participants were further classified into ages 4-24 years (birth year 1996-2016) and 25-33 years (birth year 1986-1995). We described their clinical syndrome defined by the World Health Organization and examined the relation between the COVID-19 severity and BCG vaccination status. In the 4-24 age group, among 138 BCG vaccinated individuals, 80.4% were asymptomatic or had mild disease, while 17.4% had moderate disease, 1.5% had severe disease, and 0.7% had acute respiratory distress syndrome but none of them died. In contrast, all 6 BCG unvaccinated individuals in this age group experienced mild illness. In the 25-33 age group, moderate disease occurred in 14.2% and severe disease occurred in 0.9% of the 106 patients without neonatal BCG vaccination records, as compared to 19.2% had moderate disease and none had severe or critical disease of the 78 patients with neonatal BCG vaccination records. Our finding indicated that BCG immunization might not relate to COVID-19 severity in the young population.
Sections du résumé
BACKGROUND
Data have not been reported to explore the relation between COVID-19 severity and BCG vaccination status at the individual patient level.
METHODS
Taiwan has a nationwide neonatal BCG vaccination program that was launched in 1965. The Taiwan Centers for Disease Control established a web-based National Immunization Information System (NISS) in 2003 and included all citizens' BCG vaccination records in NISS for those born after 1985. We identified COVID-19 Taiwanese patients born after 1985 between 21 January and 19 March 2021. Study participants were further classified into ages 4-24 years (birth year 1996-2016) and 25-33 years (birth year 1986-1995). We described their clinical syndrome defined by the World Health Organization and examined the relation between the COVID-19 severity and BCG vaccination status.
RESULTS
In the 4-24 age group, among 138 BCG vaccinated individuals, 80.4% were asymptomatic or had mild disease, while 17.4% had moderate disease, 1.5% had severe disease, and 0.7% had acute respiratory distress syndrome but none of them died. In contrast, all 6 BCG unvaccinated individuals in this age group experienced mild illness. In the 25-33 age group, moderate disease occurred in 14.2% and severe disease occurred in 0.9% of the 106 patients without neonatal BCG vaccination records, as compared to 19.2% had moderate disease and none had severe or critical disease of the 78 patients with neonatal BCG vaccination records.
CONCLUSIONS
Our finding indicated that BCG immunization might not relate to COVID-19 severity in the young population.
Identifiants
pubmed: 33919644
pii: ijerph18084303
doi: 10.3390/ijerph18084303
pmc: PMC8074147
pii:
doi:
Substances chimiques
BCG Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Microbiol Immunol Infect. 2017 Feb;50(1):90-96
pubmed: 25732698
Vaccine. 2020 Sep 22;38(41):6374-6380
pubmed: 32798142
J Clin Invest. 2021 Jan 19;131(2):
pubmed: 33211672
PLoS One. 2020 Dec 17;15(12):e0243707
pubmed: 33332418
JAMA. 2020 Jun 9;323(22):2340-2341
pubmed: 32401274
J Pediatric Infect Dis Soc. 2019 Jul 1;8(3):213-220
pubmed: 29635419
J Innate Immun. 2014;6(2):152-8
pubmed: 24192057
Disaster Med Public Health Prep. 2020 Jul 14;:1-7
pubmed: 32660677
Epidemiol Infect. 2021 Mar 16;149:e75
pubmed: 33722335
Nat Rev Immunol. 2020 Jun;20(6):335-337
pubmed: 32393823
J Microbiol Immunol Infect. 2020 Jun;53(3):404-412
pubmed: 32173241
Clin Infect Dis. 2020 Aug 23;:
pubmed: 32829400
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):422-426
pubmed: 32271728
Int J Environ Res Public Health. 2021 Feb 10;18(4):
pubmed: 33578829
Indian J Pediatr. 2020 Sep;87(9):749
pubmed: 32519258
J Intern Med. 2020 Dec;288(6):682-688
pubmed: 33107999
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25203-25204
pubmed: 32994350
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:202-203
pubmed: 33163696
N Engl J Med. 2020 Aug 20;383(8):e56
pubmed: 32767891
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17720-17726
pubmed: 32647056
J Formos Med Assoc. 2008 Mar;107(3):195-7
pubmed: 18400604
Lancet Infect Dis. 2016 Feb;16(2):219-26
pubmed: 26603173
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25205-25206
pubmed: 32994349
Infection. 2021 Jan 25;:
pubmed: 33495884
Allergy. 2020 Jul;75(7):1815-1819
pubmed: 32339299
Int J Environ Res Public Health. 2020 Aug 03;17(15):
pubmed: 32756371
Hum Vaccin Immunother. 2020 Dec 1;16(12):2954-2962
pubmed: 32991235
Vaccine. 2021 Jan 15;39(3):460-462
pubmed: 33341305
EMBO Mol Med. 2020 Jun 8;12(6):e12661
pubmed: 32379923
Cell. 2020 Oct 15;183(2):315-323.e9
pubmed: 32941801
Sci Rep. 2021 Jan 12;11(1):774
pubmed: 33436946